POTASSIUM CHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Potassium Chloride patents expire, and when can generic versions of Potassium Chloride launch?
Potassium Chloride is a drug marketed by Actavis Labs Fl Inc, Adare Pharms Inc, Amneal Pharms, Chartwell Molecular, Glenmark Pharms Ltd, Granules, Lupin Ltd, Nesher Pharms, Novel Labs Inc, Padagis Us, Ph Health, Prinston Inc, Strides Pharma, Teva, Tris Pharma Inc, Zydus Pharms, Ajenat Pharms, Amneal, Anda Repository, Epic Pharma Llc, Genus, Novitium Pharma, Rubicon Research, Abraxis Pharm, B Braun, Baxter Hlthcare, Fresenius Kabi Usa, Gd Searle Llc, Hospira, Intl Medication, Lilly, Luitpold, Miles, Nexus, Pharma Serve Ny, Watson Labs, Apotex, Ascent Pharms Inc, Aurobindo Pharma, Genus Lifesciences, Macleods Pharms Ltd, Pharm Assoc, Quagen, Sciegen Pharms, Taro, Wes Pharma Inc, Aurobindo Pharma Ltd, Breckenridge, Chartwell Rx, Copley Pharm, Guangzhou Novaken, Pharmobedient, Rising, Schering, Sigmapharm Labs Llc, Twi Pharms, Yichang Humanwell, Otsuka Icu Medcl, and Icu Medical Inc. and is included in one hundred and thirty-seven NDAs. There is one patent protecting this drug.
The generic ingredient in POTASSIUM CHLORIDE is calcium chloride; dextrose; potassium chloride; sodium chloride; sodium lactate. There are two hundred and eighty-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the calcium chloride; dextrose; potassium chloride; sodium chloride; sodium lactate profile page.
DrugPatentWatch® Generic Entry Outlook for Potassium Chloride
Annual sales in 2022 were $9mm indicating the motivation for generic entry (peak sales were $386mm in 2004).
Indicators of Generic Entry
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for POTASSIUM CHLORIDE?
- What are the global sales for POTASSIUM CHLORIDE?
- What is Average Wholesale Price for POTASSIUM CHLORIDE?
Summary for POTASSIUM CHLORIDE
| US Patents: | 1 |
| Applicants: | 59 |
| NDAs: | 137 |
| Finished Product Suppliers / Packagers: | 71 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Patent Applications: | 3,642 |
| Drug Prices: | Drug price information for POTASSIUM CHLORIDE |
| Drug Sales Revenues: | Drug sales revenues for POTASSIUM CHLORIDE |
| What excipients (inactive ingredients) are in POTASSIUM CHLORIDE? | POTASSIUM CHLORIDE excipients list |
| DailyMed Link: | POTASSIUM CHLORIDE at DailyMed |
Pharmacology for POTASSIUM CHLORIDE
| Drug Class | Osmotic Laxative Potassium Salt |
| Mechanism of Action | Osmotic Activity |
| Physiological Effect | Increased Large Intestinal Motility Inhibition Large Intestine Fluid/Electrolyte Absorption |
Anatomical Therapeutic Chemical (ATC) Classes for POTASSIUM CHLORIDE
US Patents and Regulatory Information for POTASSIUM CHLORIDE
POTASSIUM CHLORIDE is protected by one US patents.
Expired US Patents for POTASSIUM CHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Schering | POTASSIUM CHLORIDE | potassium chloride | TABLET, EXTENDED RELEASE;ORAL | 019439-002 | Jun 13, 1986 | ⤷ Start Trial | ⤷ Start Trial |
| Schering | POTASSIUM CHLORIDE | potassium chloride | TABLET, EXTENDED RELEASE;ORAL | 019439-001 | Jun 13, 1986 | ⤷ Start Trial | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for POTASSIUM CHLORIDE
See the table below for patents covering POTASSIUM CHLORIDE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Spain | 8801121 | ⤷ Start Trial | |
| Norway | 172375 | ⤷ Start Trial | |
| New Zealand | 215241 | SUBSTAINED RELEASE POTASSIUM CHLORIDE DOSAGE UNITS | ⤷ Start Trial |
| Norway | 864168 | ⤷ Start Trial | |
| Japan | H0625064 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for POTASSIUM CHLORIDE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1499331 | 13C0055 | France | ⤷ Start Trial | PRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: BE - 434323 20130220 |
| 0253310 | SPC/GB95/010 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215 |
| 1718641 | 2012/008 | Ireland | ⤷ Start Trial | PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTRATION NO/DATE: EU/1/11/734/001-011 EU/1/11/735/001-011 20111209 |
| 1441735 | 08C0026 | France | ⤷ Start Trial | PRODUCT NAME: RALTEGRAVIR POTASSIUM; REGISTRATION NO/DATE: EU/1/07/436/001 20080102 |
| 1499331 | SPC/GB13/034 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: IZINOVA CONCENTRATE FOR ORAL SOLUTION. THE ACTIVE SUBSTANCE IS A MIXTURE OF 3 SALTS:SODIUM SULPHATE ANHYDROUS, MAGNESIUM SULPHATE HEPTAHYDRATE AND POTASSIUM SULPHATE.; REGISTERED: BE BE434323 20130220; UK PL34926/0016 20130313 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Market Dynamics and Financial Trajectory for Potassium Chloride
More… ↓



